Kimberly Blackwell - May 16, 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
President & CEO, Director
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kimberly Blackwell
Stock symbol
ZNTL
Transactions as of
May 16, 2022
Transactions value $
$0
Form type
4
Date filed
5/20/2022, 04:27 PM
Previous filing
Jan 5, 2022
Next filing
Jun 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +1.71M $0.00 1.71M May 16, 2022 Common Stock 1.71M $24.41 Direct F1
transaction ZNTL Stock Option (Right to Buy) Award $0 +427K $0.00 427K May 16, 2022 Common Stock 427K $24.41 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the shares on May 16, 2023 and vests in equal monthly installments thereafter until May 16, 2026.
F2 The option vests and becomes exercisable as to 100% of the shares on the earlier of (a) FDA approval of a Zentalis product or (b) a Change in Control (as defined in the Issuer's 2020 Incentive Award Plan).